Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation

In order to inform policy work and clinical decisions, a health technology assessment was undertaken by CADTH. For this project CADTH worked in partnership with the Canadian Collaboration for Drug Safety, Effectiveness and Network Meta-Analysis (ccNMA), funded by the Drug Safety and Effectiveness Network (DSEN) of the Canadian Institutes of Health Research (CIHR). The health technology assessment includes both a clinical and an economic evaluation. The clinical component was conducted by ccNMA, and the economic evaluation was conducted by CADTH. This report provides findings from the economic evaluation.The economic evaluation was undertaken to inform the rational use of direct oral anticoagulants (DOACs) and ensure health care system sustainability; it aimed to determine the cost-effectiveness of anticoagulation treatment strategies for patients with venous thromboembolic events (VTEs). This was done in close collaboration with ccNMA, which conducted a rigorous systematic review of randomized controlled trials and a network meta-analysis (NMA) used to inform the relative efficacy and safety in the economic evaluation. Findings from the economic evaluation are presented in this report; the results of the clinical evaluation are available at: https://www.ottawaheart.ca/researchers/resources-services/core-facilities/cardiovascular-research-methods-centre